Group items tagged

Kamila Hawthorne, the chair of the Royal College of General Practitioners (RCGP) Council, was honoured with the GG2 Woman of the Year Award at the annual GG2 Leadership and Diversity Awards, held at the Park Plaza Hotel on Tuesday, 5 March. Hawthorne has been a practitioner and a mentor to young GPs for almost 35 years, and has led pioneering research projects focusing on health inequalities, diabetes and heart disease. She has been recognised twice as GP of the Year for her work with minority ethnic communities. Professor Kiran Patel, Group Chief Medical Officer at University Hospitals Birmingham NHS Foundation Trust, was named the GG2 Man of the Year Award. Apart from being a sought-after cardiologist and consultant, Patel also possesses a wealth of experience in managerial roles. He has done a lot of work in addressing health inequalities, and notably, in 2020, he prescribed the very first COVID-19 vaccine.

Reacting to recommendations from a UK-first independent review, the Department of Health and Social Care (DHSC) has outlined action to tackle potential bias in the design and use of medical devices. Professor Dame Margaret Whitehead, professor of public health at the University of Liverpool, was appointed to lead the review, which focused on three areas - optical devices such as pulse oximeters, AI-enabled devices, and polygenic risk scores (PRS) in genomics. The DHSC commissioned the medical devices review after concerns were raised that pulse oximeters - widely used during the COVID-19 pandemic to monitor blood oxygen levels - were not as accurate for patients with darker skin tones. There were worries that this could cause delays in treatment if dangerously low oxygen levels in such patients were missed. However, no evidence was found from NHS studies indicating that this differing performance had an impact on patient care. Accepting the report's conclusions, the DHSC has committed to several actions, such as ensuring the safe use of pulse oximeter devices across a range of skin tones within the NHS and eliminating racial bias from data sets employed in clinical studies.

Navigating the complex world of medical insurance can often feel overwhelming, with a myriad of plans, coverage options, and terminologies to understand. However, being well-informed about medical insurance is crucial to making educated decisions that ensure you and your loved ones are adequately protected in times of health emergencies. This blog aims to demystify some of the essential aspects of medical insurance, providing you with 6 crucial pieces of information that everyone should know. Whether you're purchasing your first policy or looking to better understand your current plan, this guide is designed to empower you with the knowledge needed to make informed choices about your healthcare coverage. Expat Options For expatriates living and working away from their home countries, having reliable medical insurance is not just important-it's essential. Navigating healthcare systems in a foreign country can be daunting, and without proper coverage, the financial implications of medical emergencies can be severe. For example, in Dubai medical insurance for your wife's dependents is mandatory, and in the United States, medical bills can easily rack up into the thousands for even minor treatments. Therefore, expats should research their options carefully and ensure that they have comprehensive coverage that meets their specific needs.

British Pharma giant, GSK is planning to invest more than £200 million (about $253 million) into the United Kingdom over the next two years to strengthen its manufacturing network. The money will be used to improve the pharmaceutical group's UK sites, including construction of new facilities and assembly lines, The Daily Mail first reported on Sunday. GSK has already earmarked £67 million to upgrade its manufacturing site in Montrose, Scotland, where a new production facility is being constructed. The upgrade is expected to help boost its production of active pharmaceutical ingredients (API) for the future supply of medicines. Regis Simard, head of global supply chain, told the publication that their six UK manufacturing sites, including Montrose, are an important part of their global manufacturing network.

Cancer patients in the UK are being given a new immunotherapy treatment at Imperial College Healthcare NHS Trust as part of a global phase 1/2 clinical trial, which aims to evaluate its safety and potential for treating 'solid tumour' cancers such as melanoma and lung cancer. The experimental therapy, called mRNA-4359, has been designed to train patients' immune systems to recognise and fight cancer cells, according to researchers at Imperial College London. For the first time in the UK, cancer patients received the treatment at the National Institute for Health and Care Research (NIHR) Imperial Clinical Research Facility at Hammersmith Hospital. In this non-randomised trial, mRNA-4359 is administered to patients either alone or in combination with an existing cancer drug called pembrolizumab, a type of immune checkpoint inhibitor. The researchers are hopeful that this new therapeutic approach, if proven to be safe and effective in clinical trials, could lead to a new treatment option for difficult-to-treat cancers.

Global healthcare company Mundipharma and Vectura, an inhalation contract development and manufacturing organization, have entered into a collaboration agreement aimed at reformulating an asthma inhaler as part of their commitment to reducing the product's carbon footprint. The companies will be working together on incorporating an environmentally friendly propellant into the formulation of flutiform, a pressurised metered-dose inhaler (pMDI) used for asthma treatment, to achieve a near-zero-emissions product. Currently, the product uses the approved apaflurane hydrofluoroalkane 227 (HFA-227), a type of fluorinated greenhouse gas, as its propellant. The European Union's regulation on these types of greenhouse gases targets a two-thirds reduction in their usage and subsequent emissions by 2030. In a joint statement, companies revealed that work is already in progress to find an alternative to the HFA-227 gas. Yuri Martina, Chief Development and Medical Officer at Mundipharma, said: "This is the first step in our long-term plan to develop a near-zero-emissions asthma inhaler.

In the next 10 years, the incidence of first-time stroke cases in the UK is projected to increase by 60 per cent, costing the government £75bn in healthcare and lost productivity, a charity has suggested. A new manifesto published by the Stroke Association has urged the next UK government to make stroke "the priority", stressing that the next decade is crucial for stroke prevention, treatment and recovery. Currently, stroke is the UK's fourth biggest killer and a leading cause of disability. On a daily basis, 281 individuals experience a stroke. Next year, the cost of stroke in the UK will be £43 billion. The charity predicted that by 2035, there will be 151,000 hospital admissions due to stroke every year, averaging 414 admissions per day, with 42,000 people estimated to die every year. In 2035, the UK is projected to have 2.1 million stroke survivors, imposing a financial burden of £75 billion on the public purse, nearly half the current NHS budget.

In a groundbreaking move, the Department of Education has initiated the first phase of its ambitious childcare expansion plan, offering a lifeline to thousands of working parents of two-year-olds nationwide. Effective from April 1, working parents now have access to 15 hours a week of government-funded childcare, marking the onset of the largest-ever childcare provision expansion in the country's history. This milestone initiative aims to alleviate the financial strain on families and promote workforce participation, with over 150,000 children projected to benefit from government-funded places. By September 2025, the expansion will culminate in working parents gaining access to 30 hours of free childcare, offering substantial annual savings and enabling parents to navigate the delicate balance between work and family commitments. Acknowledging the pivotal role of childcare in supporting families and driving economic growth, Prime Minister Rishi Sunak emphasized the government's commitment to delivering on its promise of expanded childcare provision.

Patients suffering from chronic and episodic migraine attacks are set to benefit from a groundbreaking recommendation by the National Institute for Health and Care Excellence (NICE) regarding a new medication. The atogepant, a first-of-its-kind preventive drug for migraine, offers hope for those grappling with this debilitating condition and can be taken orally. Published as part of the final guidance draft, NICE has greenlit the atogepant, also known as Aquipta and manufactured by AbbVie, as an option for preventing both chronic and episodic migraines in adults. Specifically, this recommendation is for individuals who have experienced at least four migraine days per month and have failed to find relief with at least three previous preventive treatments. With approximately 4.5 million people in the UK affected by various forms of migraine, this new recommendation marks a significant advancement in migraine management as the condition significantly impacts patients' day-to-day activities as well as places a heavy burden on the NHS and the wider economy.

The severity of the ADHD medication shortage in the UK has been exposed as former Hollywood extra Lee Cato revealed that he was forced to quit his job but hasn't been able to access his medicine. A resident of Berkhamsted, Hertfordshire, Lee had worked as a film extra in big movies like 'Thor' and 'Edge of Tomorrow'. The 48-year-old told Mirror that he has been taking Concerta for years to manage ADHD symptoms, but he hasn't been able to get the drug or any alternatives for over a month. He said that he first experienced shortages of the medicine in December 2023 but was initially able to take Delmosart, which he took to maintain focus despite experiencing its side effects such as headaches, nausea, tooth erosion, and a dry mouth. But now, he can't get access to any of these ADHD drugs as "they're completely out-of-stock and it's been over a month now." His chemist also tried to get hold of his medication but failed.

In a bid to address the ongoing deficit in staff in the UK's healthcare system, the National Health Service (NHS) has entered into a new workforce agreement with India. According to media reports, the healthcare service plans to hire 2,000 doctors from India on a fast-track basis to alleviate this pressing issue. It is learned that the NHS has set up training centres across many Indian cities such as Mumbai, Bangalore, Nagpur, Delhi, Gurugram, Indore, Mysore, Chennai, and Calicut to provide postgraduate training for the first batch of doctors. Post their training period (which ranges from six to 12 months), these doctors will be deployed at hospitals across Britain. They will also be exempted from the Professional and Linguistic Assessments Board (PLAB) examination that is otherwise mandatory for practising in the country.

In our quest for perfect skin, the landscape of dermatology and skin care has evolved dramatically, offering breakthrough treatments and solutions. The pursuit of a blemish-free, radiant complexion is no longer a distant dream, thanks to advancements in medical aesthetics and skincare technology. From non-invasive procedures to tailor-made skincare regimens, individuals now have access to a plethora of options designed to target specific skin concerns. This article explores the cutting-edge treatments that promise to diminish imperfections and reveal flawless skin, transforming not just how we look but also how we feel about ourselves. Botox Injections Botox, or Botulinum toxin, has gained immense popularity for its ability to smooth out wrinkles and fine lines. It works by temporarily paralyzing the facial muscles responsible for creating these imperfections. The procedure involves injecting small amounts of the neurotoxin into targeted areas, such as the forehead, crow's feet, and frown lines between the brows. The effects of Botox typically last for three to four months, making it a popular choice for those seeking quick and noticeable results. The people at sdbotox.com note that it is also a popular preventative treatment for those looking to delay the formation of wrinkles. With consistent use, Botox can actually prevent fine lines and wrinkles from appearing in the first place, making it an attractive option for individuals in their late 20s and early 30s.

Asbestos poisoning is a serious health concern that can have long-lasting effects on your well-being. Exposure to asbestos fibers can lead to various health issues, including lung cancer, mesothelioma, and asbestosis. If you suspect that you've been exposed to asbestos or are experiencing symptoms related to asbestos poisoning, it's crucial to take immediate action. 1. Recognize the Symptoms The first step in dealing with asbestos poisoning is to recognize the symptoms. Common signs of asbestos exposure include shortness of breath, persistent coughing, chest pain, and fatigue. Additionally, you may experience respiratory issues such as wheezing or difficulty breathing. Exploring the use of asbestos at Honeywell in Massachusetts can help you get a better understanding of the potential risks associated with asbestos exposure and the importance of taking proactive measures to protect yourself and your loved ones from its harmful effects. It's essential to pay attention to any changes in your health and seek medical attention if you suspect asbestos exposure.

The Pharmacists' Defence Association (PDA) has submitted evidence to the NHS Pay Review Body (PRB), emphasising on the recruitment and retention of NHS pharmacists. It has urged the PRB to help the NHS achieve two important objectives - ensuring that pharmacists can achieve well-rewarded and the service is viewed as an a ppealing alternative by student pharmacists. The PDA suggested that for the NHS to remain competitive, the PRB should focus its pay approach on employees within Bands 5-8 this year. It recognised that the last recommendation from the PRB was a "flat rate increase" and it left those working in the above-mentioned bands feeling "unhappy", which led to the CSP taking strike action over pay for the first time in their history.

Pfizer on Thursday said a single dose of its new respiratory syncytial virus (RSV) vaccine Abrysvo maintained its ability to protect against the illness through a second year of respiratory disease season. The company said in a press release that the vaccine's efficacy against RSV-associated lower respiratory tract disease with three or more symptoms was 77.8 per cent through season two, compared with efficacy of 88.9 per cent after the first RSV season, which led to the shot's US approval. The data is from a late-stage trial of more than 37,000 participants being conducted in both the Northern and Southern hemispheres. Cumulative efficacy over both seasons after around 16.4 months of disease surveillance was 81.5 per cent, Pfizer said. The data is similar to the efficacy of GSK's rival RSV shot Arexvy over two seasons, which was released in June.

The Royal Pharmaceutical Society (RPS) has joined the Welsh Royal Colleges Child Health Collaborative (WRCCHC) - a newly established group comprising 20 royal colleges and professional bodies that aims to improve health outcomes for children in Wales. Together they have written to the First Minister of Wales asking how his government will improve child health and support the workforce that care for them. Citing recent reports published by the Academy of Medical Royal Colleges and the Academy of Medical Sciences that highlighted declining health among children, they have warned of the impact of poor child health. The WRCCHC aims to ensure a sharper focus and understanding on the current and necessary support required for babies, children and young people and the workforce they represent. RPS Wales will be represented in the group by Anthony Lewis, Children and Women Lead Pharmacist at Cardiff and Vale University Health Board.

NHS England has confirmed the initial sites that will test and implement Martha's Rule in the first phase of the programme. This follows the announcement in February regarding NHSE funding for the major patient safety initiative for this financial year. The scheme is named after Martha Mills, who died from sepsis at the age of 13 in 2021. She had been treated at King's College Hospital, London, where a failure to escalate her to intensive care and a lack of response to her family's concerns about her deteriorating condition contributed to her death. Martha's Rule aims to provide a consistent and understandable way for patients and families to seek an urgent review if their or their loved one's condition deteriorates and they are concerned this is not being responded to. NHS England on Monday (27 May) announced that the scheme will be implemented at 143 hospital sites across the country by March 2025.

Thousands of cancer patients in England are set to gain fast-tracked access to personalised cancer vaccine trials through a new National Health Service(NHS) initiative, the Cancer Vaccine Launch Pad. This groundbreaking service aims to find new life-saving treatments by matching eligible patients with clinical trials across the country. The first patient to receive a personalised vaccine for bowel cancer is Elliot Phebve, a 55-year-old lecturer, treated at University Hospitals Birmingham NHS Foundation Trust. Phebve, diagnosed through a routine health check, underwent surgery and chemotherapy before joining the trial. Sponsored by German biotech company BioNTech SE, the colorectal cancer vaccine trial is one of several taking place across NHS trusts.

For the first time in Himachal Pradesh, a complete Multispeciality Hospital with Modular OT, ICU & in-house CT, MRI, USG & other Diagnostic Services under one roof. Highly experienced and competent Specialists/ Super Specialists available in the field of Medicine/ Obstetrics & Gynaecology/ General & Laparoscopic Surgery/ Radiodiagnostics/ Anaesthesia, Critical Care & ICU.